Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - diamorphine hydrochloride - powder for solution for injection - 100mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - diamorphine hydrochloride - powder for solution for injection - 500mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - diamorphine hydrochloride - powder for solution for injection - 100mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - diamorphine hydrochloride - powder for solution for injection - 500mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - diamorphine hydrochloride - powder for solution for injection - 5mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - diamorphine hydrochloride - powder for solution for injection - 10mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - diamorphine hydrochloride - powder for solution for injection - 30mg

Egyesült Államok - angol - NLM (National Library of Medicine)

direct rx - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 30 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. morphine sulfate extended-release tablets are contraindicated in patients with: significant respiratory depression acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.988 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; citric acid; sodium citrate; sodium chloride; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Izrael - angol - Ministry of Health

rafa laboratories ltd - morphine sulfate - solution for injection - morphine sulfate 20 mg/ml - morphine - morphine - morphine injection 20 mg/ml is a systemic opioid analgesic indicated only for iv, epidural and intrathecal infusion in the treatment of intractable chronic pain. it was developed for use in continuous microinfusion devices and the dosage requirements of the individual patient. morphine injetion 20 mg/ml is primarily intended for patients who are opioid -tolerant. morphine sulfate administered epidurally or intrathecally provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function